AKT1 and ovarian carcinoma: This supports earlier observations that activation of the Akt/mTOR pathway contributes to cisplatin resistance in ovarian cancer cells.45 Resistance to cisplatin, the key drug in treatment of HGSOC, may explain the worsened outcomes associated with Y163C.